简体中文 繁体中文 English 设为首页 加入收藏
  您当前的位置 :中国医学科学院血液学研究所血液病医院 > English
 Institute

Institute of Hematology & Blood Diseases Hospital
Chinese Academy of Medical Sciences & Peking Union Medical College

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Hematology and Blood Diseases Hospital (IH), Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), the biggest professional hematological institution characterized by combined basic medical research with clinical services, was established by Prof. Jiadong Deng, a famous hematologist and educationist, in Tianjin in 1957. IH was found by the former 13th Medical School of the Chinese People's Liberation Army (CPLA) (also called the 259th hospitals of the CPLA). In 1958, IH was under the charge of Ministry of Public Health and renamed as the Institute of Blood Transfusion and Hematology of CAMS, and the affiliated hospital was set up at that time. In 1970, IH was moved to Jianyang county of Sichuan province and became the branch of the CAMS. In 1979, IH was moved back to Tianjin and changed to its current name in 1987. After 50 years of development, IH becomes the largest professional hematological institution characterized by combined medical treatment with scientific research, teaching and industrialization by taking the spirit of “Rigorousness, Erudition Expertise, Creation, and Dedication”.IH have obtained a lot of outstanding achievements in research, prevention and treatment of blood diseases, new drug development and medical personnel training, etc., and enjoyed higher reputation at home and abroad.

The IH occupies an area of 40,000 square meters and the construction area was 47,000 square meters, with well-equipped network. IH consists of research and medical teams with a well-balanced faculty structure in age and specialties, an excellent academic capability and creative spirit There is a total of 795 staff in IH and the professional personnel is 676, including 23 professors, 64 associate professors, 10 mentors for doctoral degree and 22 for master degree, 4 awarded as outstanding contribution experts, 2 awarded Cheung Kong Scholars, and 2 recipients of National Outstanding Young Foundation, 2 selected by national “Millions of Talents program”, 1 well-known doctor of Chinese Academy of Medical Sciences, 2 awarded “Ten Best” medical personnel of Tianjin medical industry.

IH is the locations of the State Key Laboratory of Experimental Hematology, National Center of Stem Cell Engineering and Technology. It also is the Base of National Key Discipline on Blood Diseases, medicine pharmacology and cell molecular biology, accredited by National Ministry of Education, the Clinical Trial Base of New Drugs for Blood Diseases of the State Drug Administration (SDA), and the First Clinical Branch of National Medical Emergency Center for Nuclear Accidents. As the representative of China, IH is a member of the World Federation of Hemophilia. It is also responsible for editing and publishing “Chinese Journal of Hematology”.

The hospital is the “First Class of the Third Grade Hospital” with 520 beds. There are 11 clinical centers working respectively on anemia, leukemia, stem cell transplantation, lymphoma, pediatric hematology, MDS, thrombosis and hemostasis, first-aid treatment of the blood disease, comprehensive medical service, expert consultation and clinical laboratory medicine. The hospital provides high level of diagnosis and treatment for common, especially severe blood diseases. The diagnosis and treatment for blood diseases lead the highest level in China. The complete remission (CR) rate for adult acute myeloid leukemia is over 80%, and the 5-year survival rate of CR patients has reached above 50%. The 5-year survival rate for severe aplastic anemia is over 70%. Since the first autologous bone marrow transplantation (BMT) in China carried out in the hospital in 1987, there were more than 560 patients received BMT and the 5-year survival rate were over 50%. The curative effect for childhood blood diseases reached the international advanced level, the 5-year survival rate of childhood acute lymphoblastic leukemia is 75%~80%, and that of childhood acute myeloid leukemia is 40%~60%, in which the childhood acute promyeloid leukemia achieves the survival rate of 85%. The multidisciplinary clinical laboratory medicine center consists of 13 specialized laboratories, including clinical laboratory technology, Clinical Biochemistry, Clinical Immunology, Clinical Microbiology, hemolysis and coagulation test, cell morphology analysis, clinical chemistry, chromosomal analysis, cell culture, flow cytometry, clinical molecular biology, Nuclear Medicine and pathology. There are more than 400 test items carried out in the clinical laboratory medicine center, which covers the examination for the diagnosis of blood diseases. There are several well-known hematologists in the expert consultation center to provide advice of the diagnosis, treatment and prognosis for patients with severe and intricate blood diseases. The outpatients from all parts of the country and part of regions in Asia are around 40,000 annually.

The research part of the institute consists of 6 departments: hematopoietic stem cells; thrombosis, hemostasis and vascular biology; materia medica and pharmacology; cellular and molecular biology; immunology and biotherapy; and molecular biology of hematological oncology. The main aspects of research are the study of hematopoietic stem cell biology and plasticity, basic and applied study of hematopoiesis regulation and angiogenesis regulators, study on development of normal and abnormal hematopoietic cells and lymphocytes, especially the mechanisms, diagnosis and treatment of hematological malignancy. IH has set up six major technological platforms for stem cell banking, stem cell transplantation, antibody development, GMP pilot-scale production of genetic engineering drugs, high through-put screening of drug technology and SPF experiment animal facility.

Since the establishment of scientific funds system in our country, there were about 399 research projects carried on in IH, including National Science and Technology projects, National High Technology Research and Development Program (863 programs), State Key Development Program for Basic Research of China (973 programs), National Climb Plan, National Natural Science Funds for Distinguished Young Scholar, 144 National Natural Science Foundations of China and 176 provincial and ministerial funds. The IH has won 130 ministerial scientific prizes, obtained 24 domestic patents. There were 80 books and 4332 scientific articles published, of them 206 were SCI cited from 1997.

There are 4 doctoral programs at IH, 131 doctoral students graduated and 79 under study. There are 8 master's degree programs, 164 master degree candidates graduated and 196 under study. Several domestic and international post-doctorial researchers have already trained in the post-doctoral research station. IH has provided training for more than 1600 doctors and researchers of advanced studies from all over the country; most of them become the technical mainstays in the research and clinical treatment.

The institute launches international exchanges and cooperation actively. There are good scientific research and personnel's exchange cooperation between the IH and the National Heart, Lung, and Blood Institute (NHLBI) of NIH, IVS in France, Hemophilia centre of Foothills hospital/Calgary university, Hong Kong University of Science and Technology, etc.

IH have also made remarkable progress in industrialization of research achievement. Stem cell derived products industrialization project based on stem cell related technology and monoclonal antibody development technology was considered as one of the most important industrialization projects in Tianjin, and the example project of the high-tech product industrialization. In 2001, IH and some other shareholders established a company named “ Tianjin Union Stem Cell and Gene Engineering Co. Ltd.”. The Tianjin Cord Blood Hematopoietic Stem Cell Bank that met the international standard was set up, and passed the acceptance review and obtained the practicing certificate of Ministry of Public Health, and was accepted as member of Asia Cord Blood Bank Organization.

Facing the new development opportunities and challenges, all the staffs of IH will do our best to help in strengthening the connotation construction of the hospital culture, establishing a harmony and stable hospital environment, reinforcing the construction of scientific innovation system, cultivating and bringing up a high-level of innovation team. We have confidence in IH to be a national first-rate and internationally famous hospital specialized in hematology. We will keep the spirit of PUMC “Rigorousness, Erudition Expertise, Creation, and Dedication”, serve the people heart and soul, and work for the development of hematology.

  网站导航 | 联系我们 | 使用帮助 | 网站声明
主办:中国医学科学院血液研究所血液病医院 技术支持:北方网
您是第211257位访问者 备案序号:津ICP备******号
建议使用IE5.5以上浏览器,分辨率1024*768